Price
CHART BY
Frequently asked questions
What is Telix Pharms's market capitalization?
What is Telix Pharms's Price-to-Earnings (P/E) ratio?
What is the free float of Telix Pharms's shares?
Financials
- Market Cap
- 3.47B
- Free Float
- 276.07M
- P/E ratio (TTM)
- 103.34
Pricing
- 1D span
- $11.35$11.57
- 52W span
- $5.936$12.50
Information
Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- AU000000TLX2
- Primary Ticker
- TLX